Project Grant K08CA300940
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $235K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Grant Award Summary This Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) on September 3, 2025, provides $241,884 to Dana-Farber Cancer Institute to support a five-year research and training initiative focused on immune evasion mechanisms in diffuse large B-cell lymphoma (DLBCL). The grant funds Dr. Cynthia Hahn's research program investigating how HLA-E (human leukocyte antigen-E), a non-classical HLA class I...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $170,641 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) for the period August 1, 2025 through July 31, 2027. The award supports research training and investigator development focused on advancing understanding of tumor-immune interactions in colorectal cancer through multimodal spatial profiling analysis. The project will utilize highly multiplexed...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. a Project Grant totaling $683,075 under the Cancer Cause and Prevention Research program (CFDA 93.393) on March 24, 2026. This five-year research project, scheduled for completion on February 28, 2031, investigates the mitotic function of 53BP1 and its negative regulator TIRR (TIRR/53BP1 Complex Regulates Mitotic Fidelity and Immune-Mediated Radiation Response). The research examines how...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $445,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective March 10, 2026, with completion anticipated by December 31, 2032. The research project aims to elucidate the origins and drivers of clonal dynamics in hematopoiesis by investigating how hematopoietic stem cell (HSC) clones expand and dominate blood cell...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.71 million project grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded September 1, 2025, with a completion date of July 31, 2032. The award supports research into novel approaches for targeting cell cycle proteins in cancer treatment, specifically addressing limitations of current cyclin-dependent kinase (CDK) inhibitors. The research focuses on...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.602M Project Grant award from the National Institute of Environmental Health Sciences under the Medical Library Assistance program (CFDA 93.879) effective September 1, 2025, through August 31, 2029. The project focuses on developing computational methods for analyzing multiplex immunofluorescence (MIF) imaging data of the tumor microenvironment. The research leverages a clinically validated MIF dataset encompassing...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $275,990 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective September 2, 2025, through August 31, 2026. This award supports research and development of engineered living materials (ELMs) as programmable therapeutic implants for pancreatic ductal adenocarcinoma (PDAC), a cancer with a five-year survival rate below 5%. The project builds...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Feinstein Institutes for Medical Research a $167,500 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This research initiative addresses chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in the United States, by investigating the cellular and molecular mechanisms underlying communication between cancer cells and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. a Project Grant of $159,304 under the Cancer Research Manpower program (CFDA 93.398) for the period July 1, 2025 through June 30, 2027. This award supports research training and investigator development focused on identifying signaling pathways that govern tumoricidal macrophage function in pancreatic cancer. The project aims to elucidate receptor-ligand interactions that enable...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $151,040 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) on December 23, 2025, with a completion date of September 14, 2027. This award supports postdoctoral research training and career development focused on dissecting the structural mechanisms of oligomeric BAK (BAK oligomer), a critical executioner protein in the BCL-2 family pathway that regulates...